Related Experiment Video

Updated: Feb 5, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

869

Metabolic multimorbidity and liver fibrosis among people with hepatitis B in Senegal

Ndeye Maguette Fall1, Adrià Ramírez Mena2, Bruce Shinga Wembulua1

  • 1Service de Maladies Infectieuses et Tropicales, Fann University Hospital, Dakar, Senegal.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|February 3, 2026
PubMed

Insights

Metabolic multimorbidity, defined as multiple health conditions, was common in people with chronic hepatitis B virus (HBV) infection in Senegal. However, this study found no significant link between metabolic multimorbidity and liver fibrosis progression.

Area of Science:

  • Hepatology
  • Metabolic Diseases
  • Infectious Diseases

Background:

  • Chronic hepatitis B virus (HBV) infection is a primary cause of liver fibrosis in West Africa.
  • Metabolic comorbidities may worsen liver disease in people with HBV (pwHBV).

Purpose of the Study:

  • To assess the association between metabolic multimorbidity and liver fibrosis in pwHBV in Senegal.

Main Methods:

  • Adults testing positive for hepatitis B surface antigen and negative for HIV were included (2019-2022).
  • Metabolic multimorbidity was defined as ≥2 conditions (obesity, hypertension, diabetes, dyslipidemia).
  • Liver fibrosis was assessed using vibration controlled transient elastography (≥7.1 kPa).
  • Multivariable logistic regression analyzed the association.

Main Results:

  • 768 participants were analyzed; metabolic multimorbidity was present in 16.1% of women and 6.6% of men.
  • Significant liver fibrosis was diagnosed in 8.2% of those with and 12.2% without metabolic multimorbidity.
  • Multivariable analysis revealed no significant association between metabolic multimorbidity and liver fibrosis (aOR 1.24, 95% CI 0.51-3.03).

Conclusions:

  • Metabolic multimorbidity is more prevalent in women with chronic HBV infection in Senegal.
  • No significant association was found between metabolic multimorbidity and liver fibrosis in this cohort.
  • Further long-term studies are required to understand the impact of metabolic diseases on liver fibrosis in African pwHBV populations.
Abstract

Keywords:
Hepatitis BLiver fibrosisMetabolic multimorbiditySenegal

More Related Videos

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.9K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
201
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
233
What is Metabolism?00:52

What is Metabolism?

Overview
131.9K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
885
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K